Category Archives: Stem Cell Therapy

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Animal Stem Cell Therapy Sales Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Animal Stem Cell Therapy Sales Market Overview

The Animal Stem Cell Therapy Sales Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Animal Stem Cell Therapy Sales market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Animal Stem Cell Therapy Sales Market: Competitive Landscape

The Animal Stem Cell Therapy Sales Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Animal Stem Cell Therapy Sales Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Animal Stem Cell Therapy Sales Market Segment by Type:

Animal Stem Cell Therapy Sales Market Segment by Application:

Animal Stem Cell Therapy Sales Market Regional overview:

In the report, experts analyze and forecast the Animal Stem Cell Therapy Sales market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Animal Stem Cell Therapy Sales Market Report:

Outlook analysis of the Animal Stem Cell Therapy Sales market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Animal Stem Cell Therapy Sales market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

See the original post here:
Animal Stem Cell Therapy Sales Market Size, Share, Statistics, Trends, Demand and Revenue, Forecast To 2027 - The Haitian-Caribbean News Network

The Stem Cell Therapy for Osteoarthritis Market grew in 2019, as compared to 2018, according to our report, Stem Cell Therapy for Osteoarthritis Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Stem Cell Therapy for Osteoarthritis Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Stem Cell Therapy for Osteoarthritis Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-stem-cell-therapy-for-osteoarthritis-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Stem Cell Therapy for Osteoarthritis Market is analysed based on product types, major applications and key players

Key product type:MonotherapyCombination Therapy

Key applications:Osteoarthritis (unspecified)Knee OsteoarthritisShoulder OsteoarthritisHip Osteoarthritis

Key players or companies covered are:MesoblastRegeneusU.S. Stem CellAnterogenAsterias Biotherapeutics

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-stem-cell-therapy-for-osteoarthritis-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Stem Cell Therapy for Osteoarthritis Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Stem Cell Therapy for Osteoarthritis Market?4. What is the likely market forecast & how will be Stem Cell Therapy for Osteoarthritis Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Stem Cell Therapy for Osteoarthritis Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

View original post here:
Stem Cell Therapy for Osteoarthritis Market Division, New Business Opportunities, Growth Rate, Development Trend and Feasibility Studies 2026 -...

Fort Collins, Colorado The Stem Cell Therapy Market 2020 Research Report provides information on the market size, share, trends, growth, competitive landscape, challenges and opportunities, revenue, and forecast to 2027. Reports Globe recently incorporated a comprehensive overview of the Stem Cell Therapy market into its extensive database. The Stem Cell Therapy Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

This innovative report uses SWOT, PESTLE, and Porters Five Forces analysis to get a deeper look at the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at 117.66 million in 2019 and is projected to reach USD255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

Impact of Covid-19 on this Market:

The coronavirus pandemic (COVID-19) has affected all aspects of life around the world. The study provides a comprehensive overview of the impact of the COVID-19 pandemic on the Stem Cell Therapy market and its key segments. It also covers the current and future impact of the pandemic and offers a post-COVID-19 scenario to provide a deeper understanding of the dynamic changes in market trends and scenarios.

Competitive Landscape:

Competitive Analysis is one of the best sections of the report, comparing the progress of leading companies using key metrics like market share, new developments, global reach, local competition, pricing, and production. . From the nature of the competition to future changes in the vendor landscape, the report offers an in-depth competitive analysis in the global Stem Cell Therapy Market.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Market Segments and Sub-segments Covered in the Report are as per below:

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Research Methodology:

Reports Globe follows a comprehensive research methodology to provide the most accurate market analysis. The company relies on a data triangulation model that can be used to assess market dynamics and provide accurate estimates. Key elements of the research methodology used for all of our market reports include:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

In addition, Reports Globe has access to a wide range of reputable regional and global paid databases that help the company understand regional and global market trends and dynamics. The company analyzes the industry from a 360-degree perspective, i.e. H. From the supply and demand side, which allows us to provide detailed information about the entire ecosystem for each study. Finally, a top-down and bottom-up approach is taken to get the final search results.

It includes analysis on the following

Finally, the Stem Cell Therapy Market Report is a credible source of market research that will accelerate your business exponentially. The report gives the most important regional framework conditions, economic situations with item value, advantage, limit, production, supply, demand, market development rate and number, etc. Stem Cell Therapy Industry Report Also includes a new SWOT review task, speculative test research, and corporate return on investment research.

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the rest here:
Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media

AllTheResearch, now has a research study on the Canine Stem Cell Therapy market which delivers a precise summary of the industry estimates, SWOT analysis, industry size, profit estimation and regional outlook of the business. The report offers a concise estimation of future growth prospects and obstacles awaiting market players of this industry, while further examining their existing competitive settings and business strategies.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 year and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Key Questions Answered in the Report:

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

The research report on Canine Stem Cell Therapy market, covering the COVID-19 impact, provides a comparative analysis of the historical data with the current market scenario to unveil the growth projections for the industry over the analysis period. As per the study, the Canine Stem Cell Therapy market is expected to garner substantial returns and showcase a healthy growth rate throughout the forecast duration.

The Major Players Covered in Canine Stem Cell Therapy Market Study are:

Check all key players mentioned in this report. Lets connect with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Major Segments Covered in Canine Stem Cell Therapy Market Reports are based on types and Applications as Follows:

Based on Types Canine Stem Cell Therapy Market Segmentation:

Based on Applications Canine Stem Cell Therapy Market Segmentation:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @https://www.alltheresearch.com/impactC19-request/206

How Report will help you to make decisions for business:

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

See the original post here:
Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader

The proposed Stem Cell Therapy Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics.

The Stem Cell Therapy Market sample report includes an exclusive analysis of COVID-19 pandemic on the market space under scrutiny. The sample represents the format of the overall study which is designed to provide clarity on the structure of the report and some data points demonstrated in an attempt to provide insights into the study quality.

Furthermore, the Stem Cell Therapy Market full research study is designed on account of the fact that each segment is individually assessed and then collated to form the whole market, the study can be tailor-made to fit your exact requirements.

Request Sample Pages of this research study at https://www.theinsightpartners.com/sample/TIPHE100000991/

The structure of the Stem Cell Therapy Market report can be categorized into following sections:

The Prominent/Emerging Players in the Stem Cell Therapy Market Research include:

The Stem Cell Therapy Market Company Profiles are individually represented for all major participants and indices such as Financial Performance, Strategic Initiatives, Product Portfolio & Company Overview.

Company Overview:

Company overview provides the information about location of the company where it is headquartered along with the established year, employee strength as of 2017, regions where the company is operating and the key business areas.

Financial Performance:

Overall company/segment revenue for the year 2019, 2018, and 2017 is provided in the sub title Financial Performance (public listed companies) along with the analysis and explanation of the increase or decrease in the same due to factors such as mergers & acquisition, profit or loss in any strategic business unit (SBUs) and others.

Product Benchmarking:

Product benchmarking comprises the comprehensive list of products pertaining to the respective market along with the application and key features.

Strategic Initiatives:

Insights pertaining to the new product launch, strategic collaboration, mergers and acquisition, regulatory approval, and other developments by the company in market are covered under strategic initiatives section.

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPHE100000991/

The Stem Cell Therapy Market research study is designed keeping in focus all the major countries. Although, all these countries & their market trends were accounted for while composing it, detailed sections are available for only the spearheads. In case if you would be interested in specific countries which are not covered in the current scope, kindly share the list & we can customize the study based on the geographical scope defined by you.

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: [emailprotected]

See the article here:
Stem Cell Therapy Market Insights and Forecast by 2027 - TechnoWeekly

Oct. 28, 2020 12:00 UTC

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.(AgeX: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, and Imstem Biotechnology, Inc. (ImStem), a biopharmaceutical company developing embryonic stem cell (ESC) derived mesenchymal stem cells (MSCs), today announced that ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeXs clinical-grade ESC line ESI-053 to derive ImStems investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) from other causes.

ImStem will endeavor to file one or more investigational new drug (IND) applications for IMS001 in COVID-19 and/or ARDS with the U.S. Food and Drug Administration (FDA) or equivalent EU regulatory agency within 18 months. Under the agreement, AgeX will be entitled to receive revenues in the form of royalties on the sale of IMS001 if successfully developed by ImStem and approved for marketing by the FDA or foreign regulatory authorities, as well as a share of certain other revenues that ImStem may receive in connection with the development or commercialization of IMS001, in COVID-19 and ARDS.

This latest sublicensing arrangement between AgeX and ImStem is a continuation of AgeXs strategy to expand access to its ESI stem cell lines for use in the generation of cellular therapies. An ImStem publication in Stem Cell Reports (2014;3:115-130) showed in a mouse model of multiple sclerosis that MSCs derived from ESCs outperformed adult bone marrow MSCs. This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate. Earlier this year, the FDA cleared an IND application for IMS001 in multiple sclerosis. IMS001 is believed to be the first MSC product derived from an ESC line to be accepted for a human trial by the FDA.

Results from early clinical studies conducted in China by unrelated groups using different MSC products suggest MSCs warrant further exploration in COVID-19. First, a human study published in Aging and Disease (2020;11:216-228) showed that an intravenous infusion of adult-derived MSCs reduced COVID-19 symptoms and improved functional outcomes in seven treated patients with COVID-19 pneumonia. The MSCs appeared to be safe and well tolerated. Second, a clinical study published in Stem Cell Research & Therapy (2020;11:361) demonstrated that 12 severe COVID-19 patients who received an infusion of umbilical cord MSCs recovered without requiring mechanical ventilation and were discharged home. Even before being explored in COVID-19, MSCs were being investigated as a therapeutic option in ARDS, and emerging data in preclinical models is encouraging. However, the manufacturing scalability of adult MSCs may limit their use. ARDS is a respiratory condition characterized by inflammation and increased endothelial and epithelial permeability to protein, leading to fluid accumulation in the lungs, hemorrhage, cell injury, diffuse alveolar damage, and blockage of oxygen from getting to vital organs. ARDS affects around 200,000 patients in the U.S. every year, accounts for 10% of intensive care admissions, and has a mortality of approximately 40%, with 75,000 deaths in the U.S. annually. No specific direct therapies exist for ARDS and only supportive treatment is available.

The COVID-19 pandemic continues to impact hundreds of millions of people, with many countries now in the midst of a second wave. Antivirals, antibodies and cell therapies may all ultimately play a role in combating this disease, depending upon severity or stage. We are glad to expand our relationship with ImStem, so it can now utilize AgeXs ESI-053 stem cell line to develop its cell therapy candidate IMS001 for COVID-19 as well as acute respiratory distress syndrome more broadly, said Dr. Nafees Malik, Chief Operating Officer of AgeX. This latest sublicense is an example of AgeXs strategy to place our technologies in the hands of high-quality industry and academic partners, with this deal marking the sixth research and commercial arrangement AgeX has entered into this year.

The ESI stem cell lines are distinguished as the first clinical-grade human pluripotent stem cell lines created under current Good Manufacturing Practice as described in Cell Stem Cell (2007;1:490-4). They are listed on the National Institutes of Health (NIH) Stem Cell Registry and are among the best characterized and documented stem cell lines in the world. ESI cells are among only a few pluripotent stem cell lines from which a derived cell therapy product candidate has been granted FDA IND clearance for human studies.

We welcome the opportunity to continue to collaborate with AgeX and explore future development of our mesenchymal stem cell IMS001 product in COVID-19 and ARDS from other causes. Importantly, our product may overcome the important issue of limited manufacturing scalability associated with adult tissue derived MSCs, commented Xiaofang Wang, M.D., Chief Technology Officer of ImStem Biotechnology.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem is AgeXs delivery technology intended to stably engraft PureStem derived cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT.

For more information, please visit http://www.imstem.com.

About ES Cell International

ESI ES Cell International Pte Ltd (ESI). Established in 2000, ESI, a wholly owned subsidiary of Lineage Cell Therapeutics, Inc., developed ESI hESC lines in compliance with the principles of current Good manufacturing Practices and has made them available to various biopharmaceutical companies, universities and other research institutions, including AgeX. These ESI cell lines are extensively characterized and most of the lines have documented and publicly available genomic sequences.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs sublicense agreement with ImStem there is no assurance that (i) ImStem will be successful in developing therapeutic products from the ESI-053 stem cell line sublicensed from AgeX or that any therapeutic products that may be developed will receive FDA or foreign regulatory approval, (ii) any therapeutic products that may be developed will be successfully commercialized, or (iii) AgeX will derive revenue or other financial benefits from the sublicense agreement. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005451/en/

See the original post here:
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute...

Only two decades ago, stem cell therapy was highly regulated in the United States and other countries but it was well underway in Hadassah Hospitals labs in Jerusalem. Never would we have imagined that the US expansion of one of the key clinical trials conducted in our labs in Israel would be later funded by Californias Stem Cell Institute.

In 2004, California had the foresight to advance this critical area of research, and Hadassah advocates played a major role in the passing of an unprecedented statewide ballot initiative that authorized state funding for stem cell research. This marked the passage of Proposition 71 in 2004.

Fast forward to today. Hadassahs commitment to stem cell research led the Californians for Stem Cell, Research, Treatments and Cures Initiative effort in 2020 to reach out for help with their grassroots effort to qualify the latest stem cell funding initiative for the November ballot. It qualified with your help, and I hope that in a few short weeks well be celebrating the passage of Proposition 14, which will provide $5.5 billion to help accelerate development of treatments and cures for life-threatening diseases and conditions.

The power of stem cells is mind-blowing: We are able to use these cells to replace damaged or diseased tissue, and in this way, treatments or cures for diseases like age-related macular degeneration, ALS, MS, Parkinsons, Alzheimers and diabetes could be a reality in the foreseeable future.

I come to this subject from a place of personal sorrow.

I watched my father-in-law, Irv, suffer for 12 and a half years with ALS, a man I loved as if he were my own father. He fought and fought, he made every minute of his battle meaningful, soaking as much life as he could, until he couldnt. Irv is the reason why I became involved in Hadassah because of their cutting-edge medical research and he is the reason that Im writing to you now.

Today, Hadassah is doing incredible things in stem cell research, and the stunning results of their clinical trials have riveted the worldwide medical community.

Of course, the research most personal to me is the ALS research. Hadassah researchers conducted the worlds first clinical trial using the patients own bone marrow stem cells to treat ALS.Pikuach nefesh, the preservation of life, is the most important obligation in Judaism, and the one that drives Hadassah. With the potential of stem research, we have the ability to save millions of lives throughout the world.

And, with the promise of stem cells, we can accelerate the development of treatments and cures for life-threatening diseases and conditions that affect someone in nearly half of all California families.

I believe that stem cell research is going to allow our children to look at the major diseases that plague our modern world the way we now view polio.That potential will not reveal itself on its own, nor did it with polio. It took decades of research and funding for a polio vaccine to be fully developed, tested and made available widely.

There are no medical miracles. Medical advancement happens because of research. Research takes will, knowledge, chutzpah and, of course, money. The path to get a therapy approved by the Food and Drug Administration can take 12 to 15 years, requires thousands of patients for clinical trials and costs billions of dollars. from life-saving vaccines, to pioneering cancer treatments, to the sequencing of the human genome.w When research stalls for lack of funding, opportunities are missed. Promising avenues go unexplored.

The passage of Proposition 14 would help to overcome those hurdles and create a streamlined process that delivers much-needed treatments to patients who have few options. How amazing would it be to be part of making medical history.I am so proud to be a member of Hadassah, which is not only leading the way in stem cell research but also doing its research in service to humanity. Together, we can make medical discoveries happen and continue to set the pace for the worldwide medical community.

I wish that my father-in-law was here to give you his final thumbs up.

Stacey Dorenfeld is the National State Advocacy Co-Chair and the Hadassah Southern California Advocacy Chair.

The views and opinions expressed in this article are the authors own and do not necessarily reflect those of the Forward.

Original post:
California Proposition 14 is about pikuach nefesh heres why - Forward

The Stem Cell Therapy market study Added by Affluence Market Reports, provides an in-depth analysis pertaining to potential drivers fueling this industry. The research report on the Stem Cell Therapy market consists of significant information regarding the growth drivers, opportunities, and the challenges & restraints that define the business scenario in the subsequent years.

The report offers valuable insight into the Stem Cell Therapy market progress and approaches related to the Stem Cell Therapy market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment

Request for Sample Copy of Stem Cell Therapy Market with Complete TOC and Figures & Graphs @ https://www.affluencemarketreports.com/industry-analysis/request-sample/618347/

Key Players:

The global Stem Cell Therapy market has been comprehensively analyzed and the different companies that occupy a large percentage of the market share in the regions mentioned have been listed out in the report. Industry trends that are popular and are causing a resurgence in the market growth are identified. A strategic profile of the companies is also carried out to identify the various subsidiaries that they own in the different regions and who are responsible for daily operations in these regions.

The Key Players Covered in Stem Cell Therapy Market Study are:

For more Customization in Stem Cell Therapy Market Report:https://www.affluencemarketreports.com/industry-analysis/request-inquiry/618347/

Stem Cell Therapy Market Segmentation:

Stem Cell Therapy market is split by Type and by Application. For the period 2018-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

Impact of COVID-19 on Stem Cell Therapy Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Stem Cell Therapy Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The Stem Cell Therapy Market report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

For More Details on Impact of COVID-19 on Stem Cell Therapy Market:https://www.affluencemarketreports.com/industry-analysis/covid19-request/618347/

Regional Analysis Covered in this Report are:

Frequently Asked Questions

Get a Discount on Stem Cell Therapy Market Report @https://www.affluencemarketreports.com/industry-analysis/request-discount/618347/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For more Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number: U.S +1-(424) 256-1722

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

More here:
Stem Cell Therapy Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

Ending Disease, a forthcoming documentary directed by Emmy award-winning filmmaker Joe Gantz, explores the controversial world of stem cell researchand why it's on the frontlines of combatting incurable disease.

The four-part series follows 10 patients who suffer from debilitating illnesses including paralysis, blindness, and terminal cancer. Each patient participated in the first FDA-approved clinical trials using stem cell and CAR T-cell therapy to treat conditions that were previously deemed incurable.

Stem cells are cells with the ability to develop into other cells, allowing them to repair damaged areas of the body. Stem cell therapy, also known as regenerative medicine, involves using these cells to heal diseased, injured, or dysfunctional tissue. CAR T-cell therapy, on the other hand, is a form of immunotherapy in which a patient's T cells are collected from the blood and modified into chimeric antigen receptors (CARs).

In this exclusive Ending Disease trailer, a high school senior becomes paralyzed after suffering a neck injury during a basketball game. His parents view stem cell therapy as their son's only option to recovery:

Another woman learns that her cancer has returned, after an MRI shows lesions on her breast and lungs. "It seemed like it was a death sentence," she says in the video, and then she begins the process of CAR T-cell therapy.

"I became legally blind when I was 26; this could potentially restore my vision," a second woman shares of the revolutionary clinical trial.

Later, the documentary shows the teenage boy regaining his strength in a wheelchair, while the formerly blind woman goes rock climbing. The woman with cancer is seen playing soccer with young children.

"We have in our own bodies the cells that know how to regenerate our own bodies, so this is a real medical revolution," a healthcare worker says.

The documentary promises to be an exciting look at an ambitious clinical trial that aims to change lives for the better. Ending Disease is set to release on Friday, November 13.

You can catch a virtual screening by purchasing tickets at one of the following local participating cinemas: Gathr Films, Laemmle Virtual Cinema (Los Angeles, C.A.), The Lark (Marin County, C.A.), Tampa Theater (Tampa, F.L.), Grail Movie House (Asheville, N.C.), Cinema Art Theater (Lewes, D.E.), Real Art Ways (Hartford, C.T.), The Neon (Dayton, O.H.), Oxford Film Society (Oxford, M.S.).

Support from readers like you helps us do our best work. Go here to subscribe to Prevention and get 12 FREE gifts. And sign up for our FREE newsletter here for daily health, nutrition, and fitness advice.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

More:
Exclusive: "Ending Disease" Documentary Explores How Stem Cell Therapy Aims to Cure the Incurable - Prevention.com

Share This Article:Embryonic stem cells. Image by Prue Talbot / UC RiversideBy Dr. Larry Goldstein

A yes vote on Proposition 14 is crucial to continue the pace of medical research and our states journey to save lives. For millions of Californians who live with a chronic disease or condition, and who need new therapies, this may be their last hope. Advancing medical progress to fight devastating and life-threatening diseases and conditions is an urgent matter now.

Support Times of San Diego's growthwith a small monthly contribution

Proposition 14 will continue funding for the California Institute for Regenerative Medicine, the states stem cell research funding institute. This institute is advancing medical discoveries and treatments for dozens of life-threatening or chronic diseases and conditions, including cancer, diabetes, heart disease, Alzheimers, Parkinsons, COVID-19 and more.

It is important to understand that the federal government and the private sector wont adequately fund the development of many important stem cell therapies. While the federal government has a strong focus on early lab research, it has also effectively banned funding of many important types of stem cell research and is threatening to ban more. On the other end, private funders have different priorities when it comes to funding medical research they almost exclusively invest in late-stage clinical trials where they can profit faster at lower financial risk.

There is a glaring funding gap between early lab work and late-stage clinical trials known as The Valley of Death that often ends promising stem cell research. With the sole mission of advancing the most promising treatments and cures, the institute bridges this critical gap, ensuring that potential life-changing therapies are not left stranded. The institutes unique approach is driving our state to achieve more progress, much faster, than we could have imagined.

The institutes funding has catalyzed or funded more than 90 clinical trials, two FDA-approved cancer treatments, and nine new treatments that have been designated as breakthrough therapies and have been fast-tracked for FDA approval. These breakthroughs will potentially help patients with cancer, diabetes, kidney disease, blindness, spinal cord injuries and immunodeficiencies.

While most of the 90+ clinical trials are still underway, many lives appear to have already been saved or improved. Babies born without immune systems are now surviving as are cancer patients who have exhausted all other treatment options. The institute has funded projects to help patients with Type I Diabetes produce their own insulin, blind patients start to regain eyesight, and quadriplegics start to regain upper body function.

All of these treatments in the pipeline if and when approved will also lead to spin-off treatments because they are fundamentally changing our knowledge and approach to treating chronic diseases. For example, by saving the lives of babies born with fatal immune disorders, the new knowledge and technologies are now being applied to treat other types of disorders. Cancer therapies being developed are effectively treating a handful of cancers today, but the knowledge and technology created can be applied to treating many other forms of cancer.

If Californians do not pass Proposition 14, our journey ends here many discoveries could be left on the shelf, delaying lifesaving and life-changing treatments for years.

Furthermore, as our state recovers from the impacts of COVID-19, Proposition 14 will provide an economic stimulus it will generate additional tax revenue and create many new jobs, and it wont cost the state anything until 2026. At a time when the cost of treating chronic diseases is straining our state budget and California families, Proposition 14 seeks to fund crucial disease research at a cost of less than a fraction of 1% of what Californians spend on chronic disease annually.

Close to 100 patient advocate organizations, major chambers of commerce across the state, Gov. Gavin Newsom, federal, state and local elected officials and the University of California Regents support Proposition 14. They do so because of its promise for therapy development, new business creation, and long-term financial benefit to all Californians.

We should remember that one of Californias core strengths is innovation and creation new types of businesses, new types of scientific research, and new ways to treat chronic diseases, conditions and illnesses. We cant afford to turn our back on these important goals. Our future depends on it. I hope you join me in voting YES on Proposition 14.

Dr. Larry Goldstein is a distinguished professor on the staff of the Shiley-Marcos Alzheimers Disease Research Centerat UC San Diego.

Opinion: Proposition 14 Could Save the Life of Someone You Love was last modified: October 31st, 2020 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

View post:
Opinion: Proposition 14 Could Save the Life of Someone You Love - Times of San Diego